{"id":"NCT00478699","sponsor":"Spanish Lung Cancer Group","briefTitle":"Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)","officialTitle":"Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2015-06","completion":"2015-07","firstPosted":"2007-05-25","resultsPosted":"2024-12-12","lastUpdate":"2024-12-12"},"enrollment":500,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small-cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Docetaxel/Cisplatin control","otherNames":["Taxotere/Platinol"]},{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere"]},{"type":"DRUG","name":"Gemcitabine/Cisplatin","otherNames":["Gemzar/Platinol"]},{"type":"DRUG","name":"Docetaxel/Cisplatin","otherNames":["Taxotere/Platinol"]}],"arms":[{"label":"1 Control group","type":"ACTIVE_COMPARATOR"},{"label":"2 Experimental group","type":"EXPERIMENTAL"}],"summary":"Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.","primaryOutcome":{"measure":"Estimated Overall Survival","timeFrame":"5 years","effectByArm":[{"arm":"Control Arm","deltaMin":0.54,"sd":null},{"arm":"Experimental Arm","deltaMin":0.56,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.73"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":47,"countries":["Spain"]},"refs":{"pmids":[],"seeAlso":["http://www.gecp.org"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":108},"commonTop":["Hemoglobin","Asthenia","Nausea","Alopecia","Neutrophils"]}}